Lightlake Therapeutics files IND application for Naloxone opioid overdose nasal spray
The company also announced that it has received an additional commitment from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.